AKBA 8-K: Material agreement
Akebia Therapeutics
Filed with the SEC on · accession 0001517022-26-000089
AKBA filed a 8-K (current report) with the SEC on Nov 16, 2026. Akebia Therapeutics entered into a new senior secured term loan facility of up to $140 million with Symbiotic Capital, funding an initial $60 million tranche and repaying its prior $55 million Kreos term loan.
Summary of the filing
Akebia Therapeutics entered into a new senior secured term loan facility of up to $140 million with Symbiotic Capital, funding an initial $60 million tranche and repaying its prior $55 million Kreos term loan. The company also issued warrants to purchase 3,441,352 shares at $0.6974 per share.
Key details
✦ Ask GOAX AI about this filing — what it means for AKBA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for AKBA?
Click hereFrequently asked questions
What did AKBA file with the SEC on Nov 16, 2026?
AKBA filed a 8-K (Material agreement). Akebia Therapeutics entered into a new senior secured term loan facility of up to $140 million with Symbiotic Capital, funding an initial $60 million tranche and repaying its prior $55 million Kreos term loan. The company also issued warrants to purchase 3,441,352 shares at $0.6974 per share.
What does a material agreement mean for AKBA stock?
A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other AKBA SEC filings
- 8-K · SEC filingNov 5, 2026
- 10-Q · SEC filingNov 5, 2026
- 8-K · Delisting noticeOct 23, 2026
- 8-K · Executive departureOct 14, 2026
- 8-K · SEC filingAug 5, 2026
- 10-Q · SEC filingAug 5, 2026
- 8-K · Fda approvalJun 30, 2026
- 144 · Insider sale plannedJun 29, 2026
- 8-K · Board changeJun 22, 2026
- 8-K · SEC filingMay 7, 2026
Get alerts when AKBA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days